郭思治: 昨天大市在動力配合下突破 技術上高一線
香港股票分析師協會副主席郭思治稱,大市踏進七月份首個交易日已見突破。恆指昨天先高開136點至24563點,其後在資金力捧下逐步推上,最後更以全日最高位收市。恆指報收25124點,較上日急升697點,而全日總成交金額為1759億元。單從走勢上看,由於恆指已漸升離50天線,故暫不用擔心會有試底之險。另外,經昨天之急升,恆指已一舉重越10天線(24619點)、20天線(24572點)及100天線(24663點),即技術上已初呈欲試頂之趨勢。而所指的頂,暫該為6月10日之高位25303點。只要大市能成功升越此關,即表示自3月19日低位21139點開始之反彈,技術上已漸呈浪高於浪之形態。
昨天是七月份首個交易日。恆指是由早市之低位24563點升至收市之25124點,即走勢上是典型之由頭升到尾,且亦有達1759億元之成交金額支持。大市此番突破是在龐大動力支持下進行,故技術上該可稍看高一線。由於成交金額是走在指數前頭,故此在七月上旬時分,該有更高之指數在後頭。
永泰生物(06978.HK)的EAR為首個開始實體瘤臨床試驗的細胞免疫治療產品,以肝癌為適應症,2018年中國肝癌的新增病例超過40萬,佔全球肝癌新增病例的44.9%,相關病例由2014年的360,000宗上升到2018年的400,200宗,估計至2030年將達至506,000宗,而有關中國的細胞免疫治療產品市場規模預計於2021年至2023年,將由13億元人民幣升至102億元人民幣,以人均費用一至兩萬元人民幣,而使用次數約八至20次計,EAL的市場空間已高達720億元人民幣至3500億元人民幣,即未來之發展空間極大,投資者在照顧時不妨多加關注。(筆者為證監會持牌人士)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.